Enlivex Therapeutics Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENLV research report →
Companywww.enlivex.com
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.
- CEO
- Oren Hershkovitz
- IPO
- 2014
- Employees
- 71
- HQ
- Ness Ziona, IL
Price Chart
Valuation
- Market Cap
- $17.10M
- P/E
- 0.03
- P/S
- 0.00
- P/B
- 0.02
- EV/EBITDA
- -1.10
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 248.08%
- ROIC
- -0.49%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $1.24B · 8329.17%
- EPS
- $27.04 · 3804.11%
- Op Income
- $-15,000,000
- FCF YoY
- 20.04%
Performance & Tape
- 52W High
- $2.10
- 52W Low
- $0.66
- 50D MA
- $0.91
- 200D MA
- $1.02
- Beta
- 1.49
- Avg Volume
- 554.03K
Get TickerSpark's AI analysis on ENLV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Hershkovitz Oren | other | 0 |
| Nov 16, 23 | Hershkovitz Oren | other | 150,000 |
| Nov 24, 25 | Hershkovitz Oren | other | 60,000 |
| Mar 18, 26 | Shlosberger Shachar | other | 0 |
| Mar 7, 21 | Shlosberger Shachar | other | 1,452 |
| Dec 12, 21 | Shlosberger Shachar | other | 1,452 |
| Mar 30, 24 | Shlosberger Shachar | other | 5,000 |
| Dec 10, 22 | Shlosberger Shachar | other | 1,452 |
| Nov 24, 25 | Shlosberger Shachar | other | 10,000 |
| Nov 24, 25 | Shlosberger Shachar | other | 7,500 |
Our ENLV Coverage
We haven't published any research on ENLV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ENLV Report →